Samjin Pharm (005500) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Samjin Pharm (005500) has a cash flow conversion efficiency ratio of -0.005x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-1.43 Billion ≈ $-969.50K USD) by net assets (₩264.51 Billion ≈ $179.25 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Samjin Pharm - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Samjin Pharm's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Samjin Pharm (005500) total liabilities for a breakdown of total debt and financial obligations.
Samjin Pharm Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Samjin Pharm ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
BioInvent International AB
ST:BINV
|
0.082x |
|
Paragon Globe Bhd
KLSE:3611
|
-0.008x |
|
China ZhengTong Auto Services Holdings Limited
F:ZA0
|
-0.135x |
|
Habco Trans Maritima
JK:HATM
|
0.017x |
|
MKH Oil Palm (East Kalimantan) Berhad
KLSE:5319
|
0.065x |
|
Train Alliance Sweden AB Series B
ST:TRAIN-B
|
0.035x |
|
Gobarto S.A.
WAR:GOB
|
0.057x |
|
Shieh Yih Machinery Industry Co Ltd
TWO:4533
|
-0.001x |
Annual Cash Flow Conversion Efficiency for Samjin Pharm (2013–2024)
The table below shows the annual cash flow conversion efficiency of Samjin Pharm from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see Samjin Pharm (005500) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩261.66 Billion ≈ $177.32 Million |
₩38.15 Billion ≈ $25.86 Million |
0.146x | +364.31% |
| 2023-12-31 | ₩265.36 Billion ≈ $179.83 Million |
₩8.33 Billion ≈ $5.65 Million |
0.031x | -49.90% |
| 2022-12-31 | ₩275.86 Billion ≈ $186.95 Million |
₩17.29 Billion ≈ $11.72 Million |
0.063x | -38.75% |
| 2021-12-31 | ₩234.17 Billion ≈ $158.69 Million |
₩23.97 Billion ≈ $16.24 Million |
0.102x | -8.44% |
| 2020-12-31 | ₩213.46 Billion ≈ $144.66 Million |
₩23.86 Billion ≈ $16.17 Million |
0.112x | -6.60% |
| 2019-12-31 | ₩197.47 Billion ≈ $133.83 Million |
₩23.63 Billion ≈ $16.02 Million |
0.120x | -18.32% |
| 2018-12-31 | ₩205.32 Billion ≈ $139.14 Million |
₩30.08 Billion ≈ $20.39 Million |
0.147x | -23.97% |
| 2017-12-31 | ₩193.47 Billion ≈ $131.11 Million |
₩37.28 Billion ≈ $25.27 Million |
0.193x | -32.79% |
| 2016-12-31 | ₩169.69 Billion ≈ $115.00 Million |
₩48.66 Billion ≈ $32.97 Million |
0.287x | +124.21% |
| 2015-12-31 | ₩148.06 Billion ≈ $100.34 Million |
₩18.94 Billion ≈ $12.83 Million |
0.128x | -50.26% |
| 2014-12-31 | ₩126.04 Billion ≈ $85.42 Million |
₩32.41 Billion ≈ $21.96 Million |
0.257x | +293.92% |
| 2013-12-31 | ₩112.98 Billion ≈ $76.57 Million |
₩7.37 Billion ≈ $5.00 Million |
0.065x | -- |
About Samjin Pharm
Samjin Pharmaceuticals Co., Ltd. manufactures and sells medicine. It offers medicine in oral, drop, and injecting forms. The company provides over-the-counter medicines, such as Gevorin, an anti-infalammatory pain killer; Trestan, an appetite stimulant; Flaris, an anti-thrombotic agent; and Nutilin, a brain function improvement agent, as well as medicine for treatment of chronic diseases. It also… Read more